Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 18Lymphoma, Non-Hodgkin 7Lymphoma, Mantle-Cell 6Lymphoma, Follicular 6Lymphoma, B-Cell, Marginal Zone 6Lymphoma, B-Cell 5Waldenstrom Macroglobulinemia 3Recurrence 3Lymphoma 2Lymphoma, Large B-Cell, Diffuse 1Disease Progression 1

Interventions

Cyclophosphamide 100Rituximab 82fludarabine phosphate 46Peripheral Blood Stem Cell Transplantation 45fludarabine 43Lenalidomide 35Filgrastim 33Methotrexate 32Cytarabine 32Busulfan 32venetoclax 31Etoposide 31Cyclosporine 30Dexamethasone 29Radiotherapy 28Mycophenolic Acid 28Melphalan 28Bendamustine Hydrochloride 25Antilymphocyte Serum 25Vincristine 24Gemcitabine 24ibrutinib 22Whole-Body Irradiation 22Doxorubicin 20Tacrolimus 19Methylprednisolone 18Bortezomib 18Brentuximab Vedotin 16pembrolizumab 15Prednisone 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recurrence × ublituximab × Lymphoid × Clear all
NCT03804996 2024-04-08

Study of TG-1801 in Subjects With B-Cell Lymphoma

TG Therapeutics, Inc.

Phase 1 Completed
50 enrolled
Lymphoid

Recurrence, Lymphoma, B-Cell

NCT01647971 2022-11-21

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

TG Therapeutics, Inc.

Phase 1/2 Completed
39 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT03778073 2022-08-22

Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

TG Therapeutics, Inc.

Phase 1 Terminated
18 enrolled
Lymphoid

Recurrence, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡